Free tool
Healthcare stocks
We cover 113 companies in the Healthcare sector. The median market value in the group is $20.69B. Across the group, the median move over the past trading day is +0.79%. 69% of the 107 with a 200-day average trade above it. Price change over the past year runs from −22.1% to +60.0% across the middle 80 percent of the group, with a median of +6.9%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
113 of 2,203 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LLY.DE | Eli Lilly and Company | $1.07T | Mega cap | +73.55% |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% |
| 4AB.DE | AbbVie Inc. | $471.29B | Mega cap | +32.34% |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% |
| RHO.DE | Roche Holding AG | $370.84B | Mega cap | +41.42% |
| NOT.DE | Novartis AG | $300.14B | Mega cap | +28.89% |
| AZN.L | AstraZeneca PLC | $264.05B | Mega cap | +5.65% |
| AZN.ST | AstraZeneca PLC | $258.56B | Mega cap | +6.22% |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% |
| NVO.WA | Novo Nordisk A/S | $212.23B | Mega cap | −9.22% |
| NOVO-B.CO | Novo Nordisk A/S | $210.20B | Mega cap | −11.26% |
| NOV.DE | Novo Nordisk A/S | $209.27B | Mega cap | +15.22% |
| ABL.DE | Abbott Laboratories | $200.44B | Mega cap | −10.02% |
| GIS.DE | Gilead Sciences, Inc. | $184.35B | Large cap | +33.64% |
| PFE.DE | Pfizer Inc. | $161.11B | Large cap | +22.96% |
| DAP.DE | Danaher Corporation | $151.59B | Large cap | +6.90% |
| VX1.DE | Vertex Pharmaceuticals Incorporated | $139.82B | Large cap | +41.64% |
| BRM.DE | Bristol-Myers Squibb Company | $137.92B | Large cap | +50.84% |
| IUI1.DE | Intuitive Surgical, Inc. | $131.98B | Large cap | −21.06% |
| SYK.DE | Stryker Corporation | $126.78B | Large cap | +34.90% |
| 2M6.DE | Medtronic plc | $117.57B | Large cap | +2.65% |
| SNW.DE | Sanofi | $109.40B | Large cap | −2.82% |
| SAN.PA | Sanofi | $109.36B | Large cap | −2.60% |
| GSK.L | GSK plc | $104.16B | Large cap | +30.59% |
| GS71.DE | GSK plc | $103.63B | Large cap | +34.79% |
| A58.DE | Elevance Health, Inc. | $87.59B | Large cap | −19.30% |
| ESL.DE | EssilorLuxottica Société anonyme | $85.76B | Large cap | −39.11% |
| EL.PA | EssilorLuxottica Société anonyme | $85.31B | Large cap | −38.15% |
| RGO.DE | Regeneron Pharmaceuticals, Inc. | $84.24B | Large cap | −5.91% |
| CGN.DE | The Cigna Group | $74.86B | Large cap | −8.78% |
| MRK.DE | Merck KGaA | $70.28B | Large cap | +32.17% |
| BSX.DE | Boston Scientific Corporation | $69.12B | Large cap | −53.11% |
| 0QF.DE | Moderna, Inc. | $59.07B | Large cap | +550.51% |
| BAYN.DE | Bayer Aktiengesellschaft | $56.25B | Large cap | +76.91% |
| BAY.WA | Bayer Aktiengesellschaft | $55.90B | Large cap | +76.59% |
| EWL.DE | Edwards Lifesciences Corporation | $52.39B | Large cap | +11.65% |
| BOX.DE | Becton, Dickinson and Company | $51.84B | Large cap | +1.73% |
| SHL.DE | Siemens Healthineers AG | $51.23B | Large cap | −14.18% |
| H6D0.DE | Haleon plc | $44.85B | Large cap | +5.39% |
| HLN.L | Haleon plc | $44.62B | Large cap | +2.68% |
| IX1.DE | IDEXX Laboratories, Inc. | $44.14B | Large cap | +17.97% |
| QTS.DE | IQVIA Holdings Inc. | $43.01B | Large cap | −4.04% |
| VEE.DE | Veeva Systems Inc. | $40.02B | Large cap | +13.43% |
| 2U3.DE | Alcon Inc. | $35.20B | Large cap | −7.70% |
| ILU.DE | Illumina, Inc. | $34.08B | Large cap | +129.80% |
| DC4.DE | DexCom, Inc. | $33.35B | Large cap | +21.06% |
| IDP.DE | Biogen Inc. | $32.39B | Large cap | +65.32% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | $32.28B | Large cap | −10.21% |
| ZOE.DE | Zoetis Inc. | $32.08B | Large cap | −49.47% |
| FRE.DE | Fresenius SE & Co. KGaA | $30.43B | Large cap | +1.64% |
| 22UA.DE | BioNTech SE | $28.28B | Large cap | +14.09% |
| MTO.DE | Mettler-Toledo International Inc. | $27.92B | Large cap | +13.15% |
| PHI1.DE | Koninklijke Philips N.V. | $26.37B | Large cap | +3.22% |
| DIM.PA | Sartorius Stedim Biotech S.A. | $21.78B | Large cap | +11.64% |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $21.77B | Large cap | +11.32% |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% |
| SRT3.DE | Sartorius Aktiengesellschaft | $19.68B | Large cap | +25.88% |
| VIA.DE | Viatris Inc. | $19.41B | Large cap | +67.32% |
| QS51.DE | Straumann Holding AG | $18.40B | Large cap | −1.10% |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $16.99B | Large cap | +61.26% |
| IPN.PA | Ipsen S.A. | $15.97B | Large cap | +40.80% |
| COLO-B.CO | Coloplast A/S | $15.96B | Large cap | −20.60% |
| CBHD.DE | Coloplast A/S | $15.94B | Large cap | +7.91% |
| SRT.DE | Sartorius Aktiengesellschaft | $15.54B | Large cap | +21.79% |
| ESF0.DE | Eurofins Scientific SE | $14.67B | Large cap | +12.65% |
| ERF.PA | Eurofins Scientific SE | $14.64B | Large cap | +15.60% |
| ORNBV.HE | Orion Oyj | $13.16B | Large cap | +21.01% |
| ORNAV.HE | Orion Oyj | $13.11B | Large cap | +21.27% |
| FME.DE | Fresenius Medical Care AG | $12.64B | Large cap | −2.61% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | $12.57B | Large cap | +1.80% |
| SN.L | Smith & Nephew plc | $12.18B | Large cap | −22.42% |
| AFW.DE | Align Technology, Inc. | $11.26B | Large cap | −54.37% |
| BIM.PA | bioMérieux S.A. | $10.22B | Large cap | −35.91% |
| ABVX.PA | ABIVAX Société Anonyme | $10.21B | Large cap | +48.91% |
| DEMANT.CO | Demant A/S | $9.36B | Mid cap | +17.12% |
| WDH1.DE | Demant A/S | $9.33B | Mid cap | −5.53% |
| KRK.WA | Krka, d. d. | $9.20B | Mid cap | +30.59% |
| QIA.DE | Qiagen N.V. | $8.99B | Mid cap | −6.73% |
| ALK-B.CO | ALK-Abelló A/S | $7.26B | Mid cap | +5.09% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% |
| HLUN-B.CO | H. Lundbeck A/S | $6.47B | Mid cap | +8.99% |
| HLUN-A.CO | H. Lundbeck A/S | $6.40B | Mid cap | +29.71% |
| CTEC.L | Convatec Group PLC | $6.01B | Mid cap | −1.95% |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.61B | Mid cap | −9.62% |
| OBCK.DE | Ottobock SE & Co. KGaA | $4.40B | Mid cap | +0.68% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.08B | Mid cap | +1.26% |
| BBZA.DE | BB Biotech AG | $3.87B | Mid cap | +7.22% |
| MCOV-B.ST | Medicover AB (publ) | $3.85B | Mid cap | −8.20% |
| CAMX.ST | Camurus AB (publ) | $3.79B | Mid cap | −15.35% |
| FIE.DE | Fielmann Group AG | $3.79B | Mid cap | −27.31% |
| 22Z.DE | Zealand Pharma A/S | $3.37B | Mid cap | −28.16% |
| ZEAL.CO | Zealand Pharma A/S | $3.34B | Mid cap | −25.94% |
| VIRP.PA | Virbac SA | $3.24B | Mid cap | −2.08% |
| AFX.DE | Carl Zeiss Meditec AG | $3.19B | Mid cap | −24.83% |
| BIOA-B.ST | BioArctic AB (publ) | $3.00B | Mid cap | +12.31% |
| ASKER.ST | Asker Healthcare Group AB (publ) | $2.99B | Mid cap | −24.65% |
| B72.DE | AtaiBeckley Inc. | $2.79B | Mid cap | +59.69% |
| AMBU-B.CO | Ambu A/S | $2.69B | Mid cap | −19.13% |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% |
| EMEIS.PA | emeis Société anonyme | $2.55B | Mid cap | +10.93% |
| BAVA.CO | Bavarian Nordic A/S | $2.51B | Mid cap | −7.97% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% |
| ONT.L | Oxford Nanopore Technologies plc | $2.41B | Mid cap | −2.24% |
| DMP.DE | Dermapharm Holding SE | $2.31B | Mid cap | +27.27% |
| EKTA-B.ST | Elekta AB (publ) | $2.20B | Mid cap | +26.10% |
| HCM.L | HUTCHMED (China) Limited | $2.16B | Mid cap | −18.08% |
| GN.CO | GN Store Nord A/S | $2.13B | Mid cap | −18.50% |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% |
| GNS.L | Genus plc | $2.08B | Mid cap | −12.94% |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.